"Abatacept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069594
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225
|
| Concept/Terms |
CTLA-4-Ig- CTLA-4-Ig
- Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin
- Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin
- CTLA4-Ig
- CTLA4-Ig Immunoconjugate
- CTLA4 Ig Immunoconjugate
- Immunoconjugate, CTLA4-Ig
- CTLA4-Fc
|
Below are MeSH descriptors whose meaning is more general than "Abatacept".
Below are MeSH descriptors whose meaning is more specific than "Abatacept".
This graph shows the total number of publications written about "Abatacept" by people in this website by year, and whether "Abatacept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 6 | 6 |
| 2001 | 0 | 10 | 10 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Abatacept" by people in Profiles.
-
Cross-Regulation of F-Box Protein FBXL2 with T-bet and TNF-a during Acute and Chronic Lung Allograft Rejection. J Immunol. 2022 11 01; 209(9):1788-1795.
-
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. J Rheumatol. 2021 07; 48(7):1073-1081.
-
Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant. 2020 12; 20(12):3620-3630.
-
Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant. 2020 10; 20(10):2675-2685.
-
Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts. Clin Transplant. 2019 06; 33(6):e13531.
-
Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol. 2016 09; 28(5):460-7.
-
Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation. Transplantation. 2016 08; 100(8):1683-91.
-
Belatacept for renal rescue in lung transplant patients. Transpl Int. 2016 Apr; 29(4):453-63.
-
Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients. J Immunol. 2015 Nov 01; 195(9):4069-73.
-
Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction. Transplantation. 2014 Jan 27; 97(2):133-7.